Macrocure is picking up momentum on and off Wall Street after the wound care company’s IPO struggled to get out of the gate last summer, said the company’s CEO Nissim Mashiach. MacroCure’s lead biologic product, CureXcell, is a monthly injectable of living, human, activated white blood cells used to treat chronic and hard-to-heal wounds such as venous leg ulcers. Mashiach added that the company’s regenerative medicine treatment has been used in Israel for more than 15 years and is now in two U.S. Phase 3 double-blind studies with data expected the second half of this year. Finally, Mashiach said the company is excited about its new CFO and that it has adequate cash to get the company through a Biologic License Application filing in mid-2016.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
